A set of monoclonal antibodies was used to isolate nonneutralizable foot-and-mouth disease virus variants, and the RNAs of the variants were sequenced. Cross-neutralization studies and mapping of the amino acid changes indicated two major antigenic sites. The first site was trypsin sensitive and included the VP1 140 to 160 sequence. The second site was trypsin insensitive and included mainly VP3 residues. Two minor sites were located near VP1 169 and on the C terminus of VP1. Comparison with poliovirus type 1 and human rhinovirus 14 showed a similarity in the immunogenicity of comparable sites on the viruses.
The VP1-coding regions of foot-and-mouth disease virus (FMDV) strains isolated during 18 recent European outbreaks and of vaccine strains were determined by cDNA sequencing (3) . Comparison of the sequences revealed that most of the outbreak viruses were closely related to the vaccine strains (3) . Clearly, the use of synthetic peptides as immunogen would reduce the hazards associated with largescale production of infectious virus. Much work has been directed toward elucidating amino acid sequences that can be used to prepare peptide vaccines that will, in turn, induce neutralizing and protecting antibodies.
Two findings in particular have led to the focus of attention on VP1 and fragments derived from it. First, VP1 was found to be the only capsid protein capable of eliciting neutralizing antibodies against FMDV (1, 11) . Second, trypsin treatment of FMDV resulted in cleavage of only VP1 and a drastic reduction of infectivity and immunizing activity (27) . Strohmaier et al. have shown that peptides representing the two trypsin-sensitive areas of the virus (VP1 138 to 154 and 200 to 212) were able to induce neutralizing antibodies (25) . Inoculation of a synthetic peptide encompassing VP1 141-160 of FMDV 01 protected guinea pigs against challenge with virus (4); the 200-212 peptide was less immunogenic (4, 25) .
After a single vaccination, a chemically synthesized peptide containing VP1 residues 141 to 158 and 200 to 213 protected two of nine cattle against challenge with virulent 01 virus (7) .
A systematic search for antigenic peptides on VP1 was performed by synthesizing all hexapeptides of VP1 and measuring the binding activity to rabbit antisera (8) and to a panel of monoclonal antibodies (MAbs) raised against FMDV type A10 (14, 17) . Two reactive sets of peptides were identified in the trypsin-sensitive sites of VP1, and antisera raised against these peptides neutralized the virus (17) .
Another approach to identifying antigenic sites is to isolate variants of FMDV that escape neutralization by a MAb, to sequence their genome, and to locate the mutations responsible for the escape from neutralization. This procedure has been followed for several picornaviruses. Using a panel of MAbs against poliovirus types 1, 2, and 3, researchers established an immunodominant locus on VP1 (around amino acid 100) for types 2 and 3 and several distinct antigenic sites for poliovirus type 1 (18) . Similar conclusions were reached for poliovirus type 1 by Wimmer and coworkers (6, 28) . Sherry et al. identified four antigenic sites on human rhinovirus 14 (HRV14) (22, 23) . When sequences of poliovirus and HRV14 were aligned (A. Palmenberg, personal communication), the antigenic sites on both viruses were in similar positions. Examination of the three-dimensional structures of both viruses (10, 20) revealed that each antigenic site forms a protrusion from the viral surface. Since the three-dimensional structures of these two viruses, as well as that of mengovirus (13) , are very similar, the antigenic sites of FMDV are probably located on similar protrusions. This supposition disagrees, however, with serological results for FMDV, for which only VP1 sequences were thought to elicit neutralizing antibodies (see above). Nonetheless, nonneutralizable variants of FMDV type A10-Holland were found to be charge altered in capsid proteins VP1, VP2, and VP3 (2; S. Barteling and A. Thomas, unpublished results) . In this study the RNAs of these variants were sequenced to localize the epitopes of the MAbs and the resulting antigenic map of FMDV A10 is compared with those of HRV14 and poliovirus types 1, 2, and 3.
MATERIALS AND METHODS
MAbs. MAbs against FMDV A10, inactivated with acetyl ethyleneimine, were isolated as described for type 01 (16) and serologically characterized (2, 14, 17 
6IAA6ATCAC6TT6CT666CCCAACACATC666CT 66A6AC6C66GT66T6CA66CA6A6A6A CGCTTTACAAACCTATT66AC6T66CC6AA6CAT6TCCCACCTTCCTTT6TTTCGACGAT666 (Fig. 1) . Six amino acids differed in the VP1 131 to 151 region, confirming the variability among different subtypes in this region (3) . A total of 23 amino acid residues were changed in the structural proteins VP1, VP2, and VP3; of these, 13 were found in VP1.
H1C F S P R T N H T A H
(i) Group 1. The sequence of the variants was compared with the parental A10-Holland sequence, and the mutations are shown in Table 3 and Fig. 2 . All group 1 selected variants, except for one (see below), were mutated in the VP1 140 to 160 region. This was expected from earlier data, which revealed binding of MAbl.11 to the 144 to 150 peptide GDLGSLA (17) and from the trypsin sensitivity of all group 1 MAbs in ELISA ( Table 1 ). Classification of group 1 MAbs, based on cross-neutralization (Table 1) , was consistent with the mutations found.
An interesting double mutation was observed for one MAbl.11 variant. VP1 146, as well as VP2 132, was changed, which suggests a link between the VP1 140 to 160 area and VP2 residues (20) . A relationship between VP2 or VP3 residues and the VP1 140 to 160 sequence has already been suggested for type 01K (29) . The structure of picornaviruses, deduced by X-ray crystallography examination (10, 13, 20) , suggests that the residues around VP2 135 adjoin the residues of VP1 140 to 160. Variants with only a VP2 mutation have not yet been isolated, and so we are not able to determine whether VP2 residues form part of the antigenic site.
MAbl.11 bound to the synthetic peptide GDLGSLA (VP1 144 to 150) in ELISA (17) . The mapped mutations (Table 3) agree with the loss of binding in ELISA when VP1 146 L or VP1 149 L is replaced by any amino acid except isoleucine (17) . Correlation between the mapping of mutations and the peptide ELISA, as done for MAbl.11, was impossible for MAbl.6, since this MAb did not bind to synthetic peptides in the 140 to 160 region. Apparently, amino acids from this region constitute only part of the MAb1.6 epitope, or the epitope cannot be mimicked by a linear synthetic peptide.
1.14 FEKOD/F P (Table 3) agreed with these ELISA data.
Complete resistance of FMDV 01K to neutralization by MAb D9 correlated to the L-to-R-change at VP1 148, a residue corresponding to VP1 146 in FMDV A10. In contrast, other mutations in this site led to only partial resistance (29) . The analogous L-to-R MAbl.11 mutation in FMDV A10 also resulted in complete resistance to neutralization (Table 1) .
(ii) Group 2. (Table 3) : three residues in the lower part of the 12S protomer (20) . All MAb3.10 mutations (10 independently isolated variants) involved only VP3 70. This site corresponds to N-Ag III of poliovirus type 1 (10, 18, 28) and Nim III for HRV14 (20, 22) .
Some group 3 mutants were sequenced in the VP1 140 to 160 region to verify that the phenotype of group 3 variants was not caused by an amino acid change in the highly variable VP1 140 to 160 sequence. In accordance with serological data (Tables 1 and 2 ), no amino acids were changed.
Although residues VP3 58 to 60 in poliovirus type 1 are part of N-Ag III (containing VP3 70) and although MAb3.7 variants were changed in VP3 58, VP3 59, and VP3 61 (Table  3) , the MAb3.7 variants were neutralized by MAb3.9 (Table  1) . This discrepancy might be eliminated by raising MAbs that would cover part of the MAb3.7 and MAb3.9 epitopes. Unfortunately, no firm link could be established between MAb3.7 and group 3 MAbs. The proximity of VP3 58 to 61 and VP3 70 on the viral surface is too great to regard these amino acids as belonging to independent antigenic sites (10, 20) .
The double mutation in one MAb3.10 variant (VP2 133 and VP3 70; Table 3 ) cannot be explained. Neutralization of other MAb3.10 variants showed that mutation of VP3 70 sufficed for resistance.
Remarkably, although MAb3.27 and MAb3.29 variants reacted similarly with MAb3.9, MAb3.10, and MAb3.17, the epitopes of MAb3.27 and MAb3.29 did not seem to overlap, because MAb3.27 variants were still neutralized by MAb3.29 and vice versa ( Table 2 ). This indicates either that the viral amino acids contributing to MAb binding are different for both MAbs or that the antigenic site to which they bind is large enough to accommodate two independent epitopes.
The mutations in MAb3.27 variants showed that VP3 139 and VP3 69 (or VP3 70, both triplets being GAC) were involved in the epitope of MAb3.27 (Table 3 ; Fig. 2) . Surprisingly, one of the variants had a deletion of an amino acid residue, a phenomenon not yet described for picornaviral mutants resistant to neutralization. One variant was changed at two neighboring positions (VP3 136 and VP3 139), which suggests that both residues may belong to the epitope of MAb3. 27. A thrice-cloned MAb3.29 variant was mutated at VP2 80; this residue verged upon the VP1 140 to 160 sequence and the VP2 132 residue (20; Palmenberg, personal communication). Two single-cloned variants were changed at two and three positions: the first at VP2 80 and VP3 70 and the second at the same positions plus VP2 196 (Table 3) . Because these variants were changed at more positions, conclusions cannot be based on results with these variants. VP2 196 lies directly opposite VP3 70, however, close to the threefold axis (20) .
All three MAb3.29 variants were resistant to MAb3.9. If the distance on the viral surface between VP2 80 (MAb3.29) and VP3 70, VP3 139, and VP3 195 (MAb3.9) was spanned by one MAb molecule, the epitope bridged two protomers. In addition, MAb3.9 and MAb3.10 bound to residues near the protomer border. The location of group 3 epitopes near the protomer boundary explains the absence of reactivity of most MAb3s with 12S subunits in ELISA (2; R. Meloen and S. J. Barteling, unpublished results).
Resistance to neutralization to some group 1 MAbs of MAb3.29-resistant mutants (Table 1) (iv) MAbl5. After mapping the mutations found in the MAbiS variants (Table 3) , we understood our failure to classify this MAb. VP1 169 belongs to a distinct loop, apparently not involved in other sites. This site was barely antigenic in poliovirus type 1 (10, 28) , but was present in HRV14 and was identified as Nim IB (22) . The alignment of HRV14 with the FMDV sequence (Palmenberg, personal communication) suggests that the MAblS site is similar to Nim IB.
DISCUSSION
In this study, VP1, VP2, and VP3 of the genome of FMDV A10-Holland were sequenced (Fig. 1) . Mutants that were resistant to neutralization by a specific MAb were isolated, and their genomes were compared with that of the parent virus (Table 3) . In this way, we found amino acid residues involved in MAb binding and located epitopes by aligning amino acid sequences of picornaviruses (Palmenberg, personal communication) and by comparing those sequences with the three-dimensional structure of picornaviruses (10, 13, 20) . This is a well-established procedure for locating epitopes (6, 10, 18, 20, 22, 23) . The alignment and the comparison with three-dimensional structures strongly suggest that all altered amino acids were located on the viral surface.
The antigenic sites of poliovirus type 1, HRV14, and FMDV A10 are compared in Table 4 . Antigenic sites are designated N-Ag for poliovirus (28) and Nim for HRV (22) . The three picornaviruses have N-Ag II (Nim II) and N-Ag III in common (Fig. 2) . N-Ag II contains VP1 residues in FMDV (except for a double-mutation VP1 146 and VP2 132 for one MAbl.11 variant) and only VP2 residues in HRV 14 (23) ( Table 2 ). Poliovirus combines both sequences in one antigenic site (18, 28) . Both sequences adjoin in the picornavirus and are therefore regarded as belonging to one antigenic site (18, 20, 28) .
N-Ag III is composed of residues from many different loops (Table 4) . However, these residues make up one antigenic site (Tables 1 and 2 ). The C terminus of VP1 was included in this antigenic site in HRV14. Despite a predicted relationship based on the picornaviral structure, no relationship could be established between the C terminus and N-Ag III for FMDV and poliovirus 1 (10, 20) . N-Ag IV (the C terminus of VP1) seems unimportant in FMDV A10, since the three MAbs binding to this site (MAb2.13, MAb2.18, and MAb2.24) do not compete with polyclonal sera in ELISA (25a) ( Table 2) . Within the detection limits of the competition ELISA, the data suggest that there are no neutralizing antibodies directed against the C terminus of VP1 in sera from susceptible animals. Moreover, the neutralizing capacity of group 2 MAbs is limited (Table 2 ) (A. Thomas, unpublished data). The poor ability of the C terminus of VP1 in the complete virus to generate protecting antibodies has been previously discussed (14) . The absence in FMDV of N-Ag I (or Nim IA), a strongly immunodominant site in poliovirus type 3 (18) , has been previously noted (28) .
Competition of MAb15 with convalescent bovine (or pig) serum antibodies for binding to FMDV in ELISA showed that MAb15 competed less successfully than most of the MAbs from groups 1 and 3 (results not shown). Furthermore, MAb15 was the only MAb from our panel that recognized the antigenic site that corresponded to Nim IB (Table 1) . We conclude, therefore, that MAbiS binds to an antigenic site of minor importance in FMDV.
Peptides mimicking the epitope of MAb15 were identified by a trial-and-error method with synthetic peptide ELISA (9) . Two peptide elements were identified: WQM and HS or HT. When connected by glycine or P-alanine, these elements formed a "mimotope peptide" that bound strongly to MAb15 (9) . The amino acid that is changed in the two MAb15 variants (Q VP1 169; Table 3 ) is part of a peptide sequence close to the loop containing the tripeptide MHT (20) . Therefore, the results of synthetic peptide ELISA support the location of the MAb15 epitope. Table 4 shows a nomenclature for peptide sequences involved in each antigenic site. VP1, VP2, and VP3 are approximately equal in size, and their structures are similar, consisting of antiparallel beta-sheets connected by loops (Fig. 3) . Since the basic picornavirus structure is constant (10, 13, 20) , beta-sheets (bA-bI) and alpha-helices (aA and aB) can be uniformly designated (20) ; thus, antigenic peptide sequences extending from these sheets and helices can likewise be uniformly designated (Table 4) . For example, the well-studied FMDV loop VP1 140 to 160 (Fig. 3, top right) can be designated 1 G * H, because it is located in VP1 and connects the beta-sheets G and H. Because of the great similarity between capsid proteins 1, 2, and 3 and between picornaviruses in general, this method of naming allows a direct comparison of the antigenic sites of different picornaviruses. Furthermore, the similarity between VP1, VP2, and VP3 is immediately obvious, since, for example, antigenic sites B * C and H * I occur on all three major structural proteins.
The C terminus of VP1 cannot be definitely classified. For FMDV-A1O and poliovirus type 1 it forms a distinct antigenic site, but for HRV14 it is part of N-Ag III (22, 23) . For FMDV 01 a link was made between N-Ag II and the C terminus of VP1 (29) . Whether this failure to classify the C terminus of VP1 is virus dependent is unknown.
Of the HRV14 mutants, 86% underwent a charge shift, although theoretically only one-third should have experienced a change in amino acid charge (23 charge-neutral changes were selected with MAbl.11 or MAbl.14. Apparently a charged amino acid is not favored at positions 146 to 157 in VP1. If these amino acid residues adjoin the receptor site (20) , a charged amino acid could decrease cell receptor binding.
The importance of FMDV VP1 140 to 160 (1, 4, 7, 11, 25 ) is supported by the data in this study. However, MAbs from group 3 that bound to VP3 sequences competed with polyclonal sera from susceptible animals as well as MAbs from group 1 that bound to the VP1 140 to 160 sequence (Table 2 ) (25a). Furthermore, 12 of 23 MAbs bound to N-Ag III, and 7 MAbs bound to the trypsin-sensitive site VP1 140 to 160 (Tables 1 and 2 ). Iodination of tyrosine residues revealed that the role of VP1 in immunodominance in picomaviruses was overestimated; later studies showed that when small lysine-modifying reagents are used, VP1 to 3 of poliovirus (26) , rhinovirus (12) , and FMDV (19) are labeled (see also discussion in reference 19). The resolution of picomaviral structures revealed that VP2 and VP3 were also surface exposed (10, 13, 20) . This study clearly shows at least two important antigenic sites on FMDV: first, the well-studied VP1 sequence 140 to 160 and, second, VP2 and VP3 residues as defined in Fig. 2 . A peptide vaccine that incorporates peptides from the latter site may prove more effective than the peptide vaccines used so far.
